China Largest Factory Manufacturer sales Sodium dihydrogenorthophosphate CAS 7558-80-7 CAS NO.7558-80-7

                                PRODUCT DETAILS       

Sodium phosphate monobasic Basic information Product Name: Sodium phosphate monobasic Synonyms: SODIUM DIHYDROGEN PHOSPHATE-16O4;MONOBASICSODIUMPHOSPHATE,ANHYDROUS,USP;MONOSODIUMPHOSPHATE(BULK;SODIUMPHOSPHATEMONOBASIC,ANHYDROUS,FCC(BULK;SODIUMMONOBASICPHOSPHATE;SODIUMSALTSOFORTHOPHOSPHORICACID;NATRIUMDIHYDROGENPHOSPHATE;SODIUMDIHYDROPHOSPHATE CAS: 7558-80-7 MF: H3O4P.Na MW: 119.977 EINECS: 231-449-2 Product Categories: Chemical Synthesis;Inorganic Salts;Materials Science;Metal and Ceramic Science;Salts;Sodium;AlphabeticalBiological Buffers;Biological Buffers;BioUltra Buffers;Buffer SolutionsProtein Structural Analysis;Sodium Salts;Synthetic Reagents;Ultra-High Purity Materials;Food Additives,Medical additives;Inorganics;Optimization Reagents;X-Ray Crystallography Mol File: 7558-80-7.mol   Sodium phosphate monobasic Chemical Properties Melting point  <0°C Boiling point  100°C density  1.40 g/mL at 20 °C storage temp.  room temp solubility  H2O: 5 M, clear, colorless form  powder color  White PH 4.0 - 4.5 (25℃, 50g/L in water) pka (1) 2.15, (2) 6.82, (3) 12.38 (at 25℃) Water Solubility  Soluble in water. Insoluble in alcohol,ether and chloroform. λmax λ: 260 nm Amax: ≤0.025 λ: 280 nm Amax: ≤0.02 Sensitive  Hygroscopic Merck  14,8660 BRN  3903772 Stability: Stable. Incompatible with heavy metals, strong acids. InChIKey AJPJDKMHJJGVTQ-UHFFFAOYSA-M CAS DataBase Reference 7558-80-7(CAS DataBase Reference) EPA Substance Registry System Monosodium phosphate (7558-80-7)   Safety Information Hazard Codes  Xi Risk Statements  36/37/38-36 Safety Statements  26-36-39 WGK Germany  1 RTECS  WA1900000 F  3 TSCA  Yes HS Code  28352200 Hazardous Substances Data 7558-80-7(Hazardous Substances Data) Toxicity LD50 orally in Rabbit: 8290 mg/kg LD50 dermal Rabbit > 7940 mg/kg MSDS Information Provider Language Sodium dihydrogenorthophosphate English   Sodium phosphate monobasic Usage And Synthesis Chemical Properties White, slightly deliquescent crystals or granules. Chemical Properties The USP 32 states that monobasic sodium phosphate contains one or two molecules of water of hydration or is anhydrous. The hydrated forms of monobasic sodium phosphate occur as odorless, colorless or white, slightly deliquescent crystals. The anhydrous form occurs as a white crystalline powder or granules. Physical properties Anhydrous salt: white crystalline powder; slightly hygroscopic; forms sodium acid pyrophosphate, Na2H2P2O7 on heating above 225°C and sodium metaphosphate (NaPO3)n at about 350 to 400°C; very soluble in water, aqueous solution acidic. Monohydrate: white orthorhombic crystals or granules; density 2.04 g/cm3; loses its water of crystallization at 100°C; very soluble in water, pH of 1% solution 4.5; insoluble in alcohol. Dihydrate: large transparent crystals; orthorhombic bisphenoidal structure; density 1.915 g/cm3; decomposes at 60°C; very soluble in water; insoluble in alcohol. Uses Sodium phosphate monobasic monohydrate is used as sequestrant, emulsifier, mordant in dyeing, reagent and buffer in foods and analytical chemistry. It was applied as a fireproofing agent and for weighting silk in tanning. It is employed in manufacturing of enamels, ceramics, detergents, boiler compounds, in soldering and brazing instead of borax. Uses Sodium phosphate monobasic has been used: as a reagent for virus transfection and fiber implantation in mouse in phosphate buffer for immunocytochemistry and to detect individual catalase activity by PAGE (polyacrylamide gel electrophoresis) as a buffer for cycling assay in automated DNA extraction method as a chemical in artificial cerebro-spinal fluid (aCSF) solution for the preparation of brainstem-spinal cord from rats Uses Excipient. Production Methods Monobasic sodium phosphate is prepared by adding phosphoric acid to a hot, concentrated solution of disodium phosphate until the liquid ceases to form a precipitate with barium chloride. This solution is then concentrated and the monobasic sodium phosphate is crystallized. Preparation Monobasic sodium phosphate can be prepared by partial neutralization of phosphoric acid with sodium hydroxide in equimolar amounts: H3PO4 + NaOH → NaH2PO4 + H2O It also can be made by treating disodium hydrogen phosphate with phosphoric acid in proper stoichiometric amount: Na2HPO4 + HPO4 → 2NaH2PO4. General Description Sodium phosphate monobasic is an effective oral osmotic laxative at minimal concentration. It is used for colonic cleansing before endoscopic examination of colon. Pharmaceutical Applications Monobasic sodium phosphate is used in a wide variety of pharmaceutical formulations as a buffering agent and as a sequestering agent. Therapeutically, monobasic sodium phosphate is used as a mild saline laxative and in the treatment of hypophosphatemia. Monobasic sodium phosphate is also used in food products, for example, in baking powders, and as a dry acidulant and sequestrant. Safety Profile Poison by intramuscular route. Mdly toxic by ingestion. A human and experimental eye irritant. When heated to decomposition it emits toxic fumes of POx and Na2O. See also PHOSPHATES. Safety Monobasic sodium phosphate is widely used as an excipient in parenteral, oral, and topical pharmaceutical formulations. Phosphate occurs extensively in the body and is involved in many physiological processes since it is the principal anion of intracellular fluid. Most foods contain adequate amounts of phosphate, making hypophosphatemia virtually unknown except in certain disease states or in patients receiving total parenteral nutrition. Treatment is usually by the oral administration of up to 100 mmol of phosphate daily. Approximately two-thirds of ingested phosphate is absorbed from the gastrointestinal tract, virtually all of it being excreted in the urine, and the remainder is excreted in the feces. Excessive administration of phosphate, particularly intravenously, rectally, or in patients with renal failure, can cause hyperphosphatemia that may lead to hypocalcemia or other severe electrolyte imbalances. Adverse effects occur less frequently following oral consumption, although phosphates act as mild saline laxatives when administered orally or rectally (2–4 g of monobasic sodium phosphate in an aqueous solution is used as a laxative). Consequently, gastrointestinal disturbances including diarrhea, nausea, and vomiting may occur following the use of monobasic sodium phosphate as an excipient in oral formulations. However, the level of monobasic sodium phosphate used as an excipient in a pharmaceutical formulation is not usually associated with adverse effects. LD50 (rat, IM): 0.25 g/kg(10) LD50 (rat, oral): 8.29 g/kg storage Monobasic sodium phosphate is chemically stable, although it is slightly deliquescent. On heating at 100°C, the dihydrate loses all of its water of crystallization. On further heating, it melts with decomposition at 205℃, forming sodium hydrogen pyrophosphate, Na2H2P2O7. At 250℃ it leaves a final residue of sodium metaphosphate, NaPO3. Aqueous solutions are stable and may be sterilized by autoclaving. Monobasic sodium phosphate should be stored in an airtight container in a cool, dry place. Incompatibilities Monobasic sodium phosphate is an acid salt and is therefore generally incompatible with alkaline materials and carbonates; aqueous solutions of monobasic sodium phosphate are acidic and will cause carbonates to effervesce. Monobasic sodium phosphate should not be administered concomitantly with aluminum, calcium, or magnesium salts since they bind phosphate and could impair its absorption from the gastrointestinal tract. Interaction between calcium and phosphate, leading to the formation of insoluble calcium phosphate precipitates, is possible in parenteral admixtures. Regulatory Status GRAS listed. Accepted for use as a food additive in Europe. Included in the FDA Inactive Ingredients Database (injections; infusions; ophthalmic, oral, topical, and vaginal preparations). Included in nonparenteral and parenteral medicines licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients.   Sodium phosphate monobasic Preparation Products And Raw materials Raw materials Sodium hydroxide-->Sodium carbonate-->Sodium bicarbonate-->Phosphoric acid Preparation Products Potassium Phosphate Monobasic-->Tetrahydro-4H-pyran-4-one-->sodium hexametaphosphate-->5,6-DIHYDRO-4-METHOXY-2H-PYRAN-->Tetrahydro-4-pyranol-->Trisodium phosphate-->1,2-EPOXYCYCLODODECANE-->5-NITRO-2-FUROYL CHLORIDE-->Sodium trimetaphosphate-->Disodium pytophosphate-->N-Methylpropylamine-->Maddrell's salt for food-->monosodium phosphate anhydrous

                                                                About Our Group

Leader Biochemical Group is a large leader incorporated industry manufacturers and suppliers of advanced refined raw materials From the year of 1996 when our factory was put into production to year of 2020, our group has successively invested in more than 52 factories with shares and subordinates.We focus on manufacture Pharm & chemicals, functional active ingredients, nutritional Ingredients, health care products, cosmetics, pharmaceutical and refined feed, oil, natural plant ingredients industries to provide top quality of GMP standards products.All the invested factories' product lines cover API and intermediates, vitamins, amino acids, plant extracts, daily chemical products, cosmetics raw materials, nutrition and health care products, food additives, feed additives, essential oil products, fine chemical products and agricultural chemical raw materials And flavors and fragrances. Especially in the field of vitamins, amino acids, pharmaceutical raw materials and cosmetic raw materials, we have more than 20 years of production and sales experience. All products meet the requirements of high international export standards and have been recognized by customers all over the world. Our manufacture basement & R&D center located in National Aerospace Economic & Technical Development Zone Xi`an Shaanxi China. Now not only relying on self-cultivation and development as well as maintains good cooperative relations with many famous research institutes and universities in China. Now, we have closely cooperation with Shanghai Institute of Organic Chemistry of Chinese Academy of Science, Beijing Institute of Material Medical of Chinese Academy of Medical Science, China Pharmaceutical University, Zhejiang University. Closely cooperation with them not only integrating Science and technology resources, but also increasing the R&D speed and improving our R&D power. Offering Powerful Tech supporting Platform for group development. Keep serve the manufacture and the market as the R&D central task, focus on the technical research.  Now there are 3 technology R & D platforms including biological extract, microorganism fermentation and chemical synthesis, and can independently research and develop kinds of difficult APIs and pharmaceutical intermediates. With the strong support of China State Institute of Pharmaceutical Industry (hereinafter short for CSIPI), earlier known as Shanghai Institute of Pharmaceutical Industry (SIPI), we have unique advantages in the R & D and industrialization of high-grade, precision and advanced products.  Now our Group technical force is abundant, existing staff more that 1000 people, senior professional and technical staff accounted for more than 50% of the total number of employees, including 15 PhD research and development personnel, 5 master′ S degree in technical and management personnel 9 people. We have advanced equipment like fermentation equipment and technology also extraction, isolation, purification, synthesis with rich production experience and strict quality control system, According to the GMP required, quickly transforming the R&D results to industrial production in time, it is our advantages and our products are exported to North and South America, Europe, Middle East, Africa, and other five continents and scale the forefront in the nation, won good international reputation.  We believe only good quality can bring good cooperation, quality is our key spirit during our production, we are warmly welcome clients and partner from all over the world contact us for everlasting cooperation, Leader will be your strong, sincere and reliable partner in China.

                                                                      Our Group profiles

Our Factories production lines

                                                   Our Factories R&D ability

                        Our Factories warehouse 

                                                       Product information

Sodium phosphate monobasic Basic information Product Name: Sodium phosphate monobasic Synonyms: SODIUM DIHYDROGEN PHOSPHATE-16O4;MONOBASICSODIUMPHOSPHATE,ANHYDROUS,USP;MONOSODIUMPHOSPHATE(BULK;SODIUMPHOSPHATEMONOBASIC,ANHYDROUS,FCC(BULK;SODIUMMONOBASICPHOSPHATE;SODIUMSALTSOFORTHOPHOSPHORICACID;NATRIUMDIHYDROGENPHOSPHATE;SODIUMDIHYDROPHOSPHATE CAS: 7558-80-7 MF: H3O4P.Na MW: 119.977 EINECS: 231-449-2 Product Categories: Chemical Synthesis;Inorganic Salts;Materials Science;Metal and Ceramic Science;Salts;Sodium;AlphabeticalBiological Buffers;Biological Buffers;BioUltra Buffers;Buffer SolutionsProtein Structural Analysis;Sodium Salts;Synthetic Reagents;Ultra-High Purity Materials;Food Additives,Medical additives;Inorganics;Optimization Reagents;X-Ray Crystallography Mol File: 7558-80-7.mol   Sodium phosphate monobasic Chemical Properties Melting point  <0°C Boiling point  100°C density  1.40 g/mL at 20 °C storage temp.  room temp solubility  H2O: 5 M, clear, colorless form  powder color  White PH 4.0 - 4.5 (25℃, 50g/L in water) pka (1) 2.15, (2) 6.82, (3) 12.38 (at 25℃) Water Solubility  Soluble in water. Insoluble in alcohol,ether and chloroform. λmax λ: 260 nm Amax: ≤0.025 λ: 280 nm Amax: ≤0.02 Sensitive  Hygroscopic Merck  14,8660 BRN  3903772 Stability: Stable. Incompatible with heavy metals, strong acids. InChIKey AJPJDKMHJJGVTQ-UHFFFAOYSA-M CAS DataBase Reference 7558-80-7(CAS DataBase Reference) EPA Substance Registry System Monosodium phosphate (7558-80-7)   Safety Information Hazard Codes  Xi Risk Statements  36/37/38-36 Safety Statements  26-36-39 WGK Germany  1 RTECS  WA1900000 F  3 TSCA  Yes HS Code  28352200 Hazardous Substances Data 7558-80-7(Hazardous Substances Data) Toxicity LD50 orally in Rabbit: 8290 mg/kg LD50 dermal Rabbit > 7940 mg/kg MSDS Information Provider Language Sodium dihydrogenorthophosphate English   Sodium phosphate monobasic Usage And Synthesis Chemical Properties White, slightly deliquescent crystals or granules. Chemical Properties The USP 32 states that monobasic sodium phosphate contains one or two molecules of water of hydration or is anhydrous. The hydrated forms of monobasic sodium phosphate occur as odorless, colorless or white, slightly deliquescent crystals. The anhydrous form occurs as a white crystalline powder or granules. Physical properties Anhydrous salt: white crystalline powder; slightly hygroscopic; forms sodium acid pyrophosphate, Na2H2P2O7 on heating above 225°C and sodium metaphosphate (NaPO3)n at about 350 to 400°C; very soluble in water, aqueous solution acidic. Monohydrate: white orthorhombic crystals or granules; density 2.04 g/cm3; loses its water of crystallization at 100°C; very soluble in water, pH of 1% solution 4.5; insoluble in alcohol. Dihydrate: large transparent crystals; orthorhombic bisphenoidal structure; density 1.915 g/cm3; decomposes at 60°C; very soluble in water; insoluble in alcohol. Uses Sodium phosphate monobasic monohydrate is used as sequestrant, emulsifier, mordant in dyeing, reagent and buffer in foods and analytical chemistry. It was applied as a fireproofing agent and for weighting silk in tanning. It is employed in manufacturing of enamels, ceramics, detergents, boiler compounds, in soldering and brazing instead of borax. Uses Sodium phosphate monobasic has been used: as a reagent for virus transfection and fiber implantation in mouse in phosphate buffer for immunocytochemistry and to detect individual catalase activity by PAGE (polyacrylamide gel electrophoresis) as a buffer for cycling assay in automated DNA extraction method as a chemical in artificial cerebro-spinal fluid (aCSF) solution for the preparation of brainstem-spinal cord from rats Uses Excipient. Production Methods Monobasic sodium phosphate is prepared by adding phosphoric acid to a hot, concentrated solution of disodium phosphate until the liquid ceases to form a precipitate with barium chloride. This solution is then concentrated and the monobasic sodium phosphate is crystallized. Preparation Monobasic sodium phosphate can be prepared by partial neutralization of phosphoric acid with sodium hydroxide in equimolar amounts: H3PO4 + NaOH → NaH2PO4 + H2O It also can be made by treating disodium hydrogen phosphate with phosphoric acid in proper stoichiometric amount: Na2HPO4 + HPO4 → 2NaH2PO4. General Description Sodium phosphate monobasic is an effective oral osmotic laxative at minimal concentration. It is used for colonic cleansing before endoscopic examination of colon. Pharmaceutical Applications Monobasic sodium phosphate is used in a wide variety of pharmaceutical formulations as a buffering agent and as a sequestering agent. Therapeutically, monobasic sodium phosphate is used as a mild saline laxative and in the treatment of hypophosphatemia. Monobasic sodium phosphate is also used in food products, for example, in baking powders, and as a dry acidulant and sequestrant. Safety Profile Poison by intramuscular route. Mdly toxic by ingestion. A human and experimental eye irritant. When heated to decomposition it emits toxic fumes of POx and Na2O. See also PHOSPHATES. Safety Monobasic sodium phosphate is widely used as an excipient in parenteral, oral, and topical pharmaceutical formulations. Phosphate occurs extensively in the body and is involved in many physiological processes since it is the principal anion of intracellular fluid. Most foods contain adequate amounts of phosphate, making hypophosphatemia virtually unknown except in certain disease states or in patients receiving total parenteral nutrition. Treatment is usually by the oral administration of up to 100 mmol of phosphate daily. Approximately two-thirds of ingested phosphate is absorbed from the gastrointestinal tract, virtually all of it being excreted in the urine, and the remainder is excreted in the feces. Excessive administration of phosphate, particularly intravenously, rectally, or in patients with renal failure, can cause hyperphosphatemia that may lead to hypocalcemia or other severe electrolyte imbalances. Adverse effects occur less frequently following oral consumption, although phosphates act as mild saline laxatives when administered orally or rectally (2–4 g of monobasic sodium phosphate in an aqueous solution is used as a laxative). Consequently, gastrointestinal disturbances including diarrhea, nausea, and vomiting may occur following the use of monobasic sodium phosphate as an excipient in oral formulations. However, the level of monobasic sodium phosphate used as an excipient in a pharmaceutical formulation is not usually associated with adverse effects. LD50 (rat, IM): 0.25 g/kg(10) LD50 (rat, oral): 8.29 g/kg storage Monobasic sodium phosphate is chemically stable, although it is slightly deliquescent. On heating at 100°C, the dihydrate loses all of its water of crystallization. On further heating, it melts with decomposition at 205℃, forming sodium hydrogen pyrophosphate, Na2H2P2O7. At 250℃ it leaves a final residue of sodium metaphosphate, NaPO3. Aqueous solutions are stable and may be sterilized by autoclaving. Monobasic sodium phosphate should be stored in an airtight container in a cool, dry place. Incompatibilities Monobasic sodium phosphate is an acid salt and is therefore generally incompatible with alkaline materials and carbonates; aqueous solutions of monobasic sodium phosphate are acidic and will cause carbonates to effervesce. Monobasic sodium phosphate should not be administered concomitantly with aluminum, calcium, or magnesium salts since they bind phosphate and could impair its absorption from the gastrointestinal tract. Interaction between calcium and phosphate, leading to the formation of insoluble calcium phosphate precipitates, is possible in parenteral admixtures. Regulatory Status GRAS listed. Accepted for use as a food additive in Europe. Included in the FDA Inactive Ingredients Database (injections; infusions; ophthalmic, oral, topical, and vaginal preparations). Included in nonparenteral and parenteral medicines licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients.   Sodium phosphate monobasic Preparation Products And Raw materials Raw materials Sodium hydroxide-->Sodium carbonate-->Sodium bicarbonate-->Phosphoric acid Preparation Products Potassium Phosphate Monobasic-->Tetrahydro-4H-pyran-4-one-->sodium hexametaphosphate-->5,6-DIHYDRO-4-METHOXY-2H-PYRAN-->Tetrahydro-4-pyranol-->Trisodium phosphate-->1,2-EPOXYCYCLODODECANE-->5-NITRO-2-FUROYL CHLORIDE-->Sodium trimetaphosphate-->Disodium pytophosphate-->N-Methylpropylamine-->Maddrell's salt for food-->monosodium phosphate anhydrous